QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 fda-says-abbott-medical-issues-correction-for-heartmate-lvas-system-monitor-due-to-screen-issues-that-could-cause-unintentional-pump-stop

- Reuters

 class-action-against-abbotts-glucerna-products-proceeds-in-federal-court

WuXi AppTec employees collaborated with China's PLA on altitude sickness drugs, raising national security concerns in the U...

 rbc-capital-reiterates-outperform-on-abbott-laboratories-maintains-125-price-target

RBC Capital analyst Shagun Singh reiterates Abbott Laboratories (NYSE:ABT) with a Outperform and maintains $125 price target.

 berkshire-hathaway-chipotle-more-nyse-stocks-hit-with-trading-halts-triggered-by-technical-issues-updated

NYSE experiences trading halts Monday due to a technical issue. Stocks like Berkshire Hathaway and Chipotle are impacted.

 abbott-shares-resume-trade
Abbott Shares Resume Trade
06/03/2024 14:29:56

Core News & Articles

Tecarfarin, which recently received Orphan Drug Designation from the FDA for the prevention of thromboembolism and thrombosis i...

 goldman-sachs-initiates-coverage-on-abbott-laboratories-with-buy-rating-announces-price-target-of-121

Goldman Sachs analyst David Roman initiates coverage on Abbott Laboratories (NYSE:ABT) with a Buy rating and announces Price...

 citigroup-maintains-buy-on-abbott-laboratories-lowers-price-target-to-119

Citigroup analyst Joanna Wiensch maintains Abbott Laboratories (NYSE:ABT) with a Buy and lowers the price target from $128 t...

 jim-cramer-calls-this-healthcare-stock-a-worthy-spec-recommends-avoiding-canada-goose

Cramer recommends staying away from Canada Goose, even though it reported better-than-expected Q4 earnings.

 fda-says-abbott-recalls-heartmate-3-left-ventricular-assist-system-implant-kit-for-risk-of-blood-leakage-has-identified-heartmate-3-left-ventricular-assist-system-implant-kit-as-a-class-i-recall-abbott-reports-81-incidents-including-70-injuries-and-two-deaths-related-to-issue

- Reuters